Skip To Main Content
Mohit Manghnani on Muck Rack

Mohit Manghnani

Mumbai
As seen in: Benzinga, MSN, MSN Colombia, Markets Insider, MSN España, Aol, Yahoo Finance, Yahoo Finance Singapore, Seeking Alpha, NewsBreak, Yahoo Finanzas and
Currently, news editor @Benzinga, previously @SeekingAlpha
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mohit

Contact Mohit, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Stud Original

|
By Mohit Manghnani
| Benzinga
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced Wednesday that it has successfully completed the Phase 1a dose-escalation clinical trial of its lead cancer therapeutic candidate, TTX-MC138. It met its primary safety objectives and demonstrated durable disease stabilization in patients with advanced metastatic cancer.
Open in Who Shared View Duplicates (2) Issue with article?

EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial - FibroBiologics (N Original

|
By Mohit Manghnani
| Benzinga
FibroBiologics Inc. (NASDAQ:FBLG) on Wednesday announced that it has enrolled and dosed the first patients in its Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs). FibroBiologics Does First Patients In CYWC628 Trial FibroBiologics said it has dosed the first patients in the CYWC628 Phase 1/2 clinical trial.
Open in Who Shared View Duplicates (2) Issue with article?

How Did Ford Perform In 2025? - Ford Motor (NYSE:F)

|
By Mohit Manghnani
| Benzinga
Ford Motor Company (NYSE:F) shares are up on Tuesday following a strong sales performance reported for 2025. The stock is gaining traction as the broader market experiences positive momentum, with major indices like the S&P 500 and Nasdaq showing gains. Ford’s total sales for 2025 climbed 6% to 2,204,124 vehicles, marking the company’s highest sales year this decade.
Open in Who Shared Issue with article?
See all 6,357 articles